Anixa Biosciences is trading 10.81% up now at $3.38 after highlighting updated survival observations from its ongoing Phase 1 ovarian-cancer CAR-T trial.
- The clinical update appears to be the clearest company-specific catalyst for the September 4, 2026, pre-market move.
- Recent investor attention has focused on patients surviving beyond expectations.
- A September 9 investor presentation provided no additional clinical or financial results.